JW Pharmaceutical secures GLP-1 drug rights in $81m deal

JW Pharmaceutical said Thursday it has secured exclusive domestic rights to bofanglutide, a next-generation GLP-1 receptor agonist, under a licensing agreement with China’s Gan & Lee Pharmaceuticals. Under the deal, JW Pharmaceutical will lead development, regulatory approval and commercialization in Korea, while Gan & Lee will provide data and documentation needed for investigational new drug and product approvals. The contract is valued at up to $81.1 million, including a $5 million upfront pa

By The Korea Herald